MIA - A new target protein for malignant melanoma therapy

Histology and Histopathology

Volumn 28, Issue 4, 2013, Pages 421-426

  Schmidt, Jennifer ^a,b   Riechers, Alexander ^a   Bosserhoff, Anja Katrin ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b Fraunhofer Institut fur Festkorpertechnologie   (Germany)

Author keywords

Immunosuppression; Malignant melanoma; Metastasis; MIA; Peptide inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; MIA ANTIGEN, HUMAN; TUMOR ANTIGEN;

ANIMAL; DRUG DESIGN; DRUG EFFECT; HUMAN; IMMUNOLOGY; MELANOMA; METABOLISM; METASTASIS; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; SKIN TUMOR; TUMOR INVASION;

ANIMALS; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; ANTINEOPLASTIC AGENTS; DRUG DESIGN; HUMANS; MELANOMA; MOLECULAR TARGETED THERAPY; NEOPLASM INVASIVENESS; PROGNOSIS; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 84876435329     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Abdel-Malek Z.A., Knittel J., Kadekaro A.L., Swope V.B. and Starner R. (2008). The melanocortin 1 receptor and the UV response of human melanocytes-a shift in paradigm. Photochem. Photobiol. 84, 501-508.
2. Bauer R., Humphries M., Fassler R., Winklmeier A., Craig S.E. and Bosserhoff A.K. (2006). Regulation of integrin activity by MIA. J. Biol. Chem. 281, 11669-11677.
3. Besaratinia A. and Pfeifer G. P. (2008). Sunlight ultraviolet irradiation and BRAF V600 mutagenesis in human melanoma. Hum. Mutat. 29, 983-991.
4. Blesch A., Bosserhoff A.K., Apfel R., Behl C., Hessdoerfer B., Schmitt A., Jachimczak P., Lottspeich F., Buettner R. and Bogdahn U. (1994). Cloning of a novel malignant melanoma-derived growth-regulatory protein, MIA. Cancer Res. 54, 5695-5701.
5. Bosserhoff A.K. and Buettner R. (2003). Establishing the protein MIA (melanoma inhibitory activity) as a marker for chondrocyte differentiation. Biomaterials 24, 3229-3234.
6. Bosserhoff A.K., Kaufmann M., Kaluza B., Bartke I., Zirngibl H., Hein R., Stolz W. and Buettner R. (1997). Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res. 57, 3149-3153.
7. Bosserhoff A.K., Golob M., Buettner R., Landthaler M. and Hein R. (1998). MIA (melanoma inhibitory activity). Biological functions and clinical relevance in malignant melanoma. Hautarzt 49, 762-769.
8. Bosserhoff A.K., Echtenacher B., Hein R. and Buettner R. (2001). Functional role of melanoma inhibitory activity in regulating invasion and metastasis of malignant melanoma cells in vivo. Melanoma Res. 11, 417-421.
9. Bosserhoff A.K., Stoll R., Sleeman J.P., Bataille F., Buettner R. and Holak T.A. (2003). Active detachment involves inhibition of cell-matrix contacts of malignant melanoma cells by secretion of melanoma inhibitory activity. Lab. Invest. 83, 1583-1594.
10. Brundage R.A., Fogarty K.E., Tuft R.A. and Fay F.S. (1991). Calcium gradients underlying polarization and chemotaxis of eosinophils. Science 254, 703-706.
11. Clark E.A., Golub T.R., Lander E.S. and Hynes R.O. (2000). Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406, 532-535.
12. Cleaver J.E. and Crowley E. (2002). UV damage, DNA repair and skin carcinogenesis. Front. Biosci. 7, d1024-1043.
13. de Gruijl F.R., van Kranen H.J. and Mullenders L.H. (2001). UV-induced DNA damage, repair, mutations and oncogenic pathways in skin cancer. J. Photochem. Photobiol. B 63, 19-27.
14. Dreau D., Bosserhoff A.K., White R.L., Buettner R. and Holder W.D. (1999). Melanoma-inhibitory activity protein concentrations in blood of melanoma patients treated with immunotherapy. Oncol. Res. 11, 55-61.
15. Franco S.J. and Huttenlocher A. (2005). Regulating cell migration: calpains make the cut. J. Cell Sci. 118, 3829-3838.
16. Gammill L.S. and Bronner-Fraser M. (2002). Genomic analysis of neural crest induction. Development 129, 5731-5741.
17. Gray-Schopfer V., Wellbrock C. and Marais R. (2007). Melanoma biology and new targeted therapy. Nature 445, 851-857.
18. Greinert R. (2009). Skin cancer: new markers for better prevention. Pathobiology 76, 64-81.
19. Guba M., Bosserhoff A.K., Steinbauer M., Abels C., Anthuber M., Buettner R. and Jauch K. W. (2000). Overexpression of melanoma inhibitory activity (MIA) enhances extravasation and metastasis of Amel 3 melanoma cells in vivo. Br. J. Cancer 83, 1216-1222.
20. Hahn K., DeBiasio R. and Taylor D.L. (1992). Patterns of elevated free calcium and calmodulin activation in living cells. Nature 359, 736-738.
21. Jachimczak P., Apfel R., Bosserhoff A.K., Fabel K., Hau P., Tschertner I., Wise P., Schlingensiepen K.H., Schuler-Thurner B. and Bogdahn U. (2005). Inhibition of immunosuppressive effects of melanoma-inhibiting activity (MIA) by antisense techniques. Int. J. Cancer 113, 88-92.
22. + channels inhibit human pancreatic cancer cell growth in vitro. Mol. Pharmacol. 65, 630-638.
23. 2+ transients control CNS neuronal migration. Cell Calcium 37, 387-393.
24. Lallet-Daher H., Roudbaraki M., Bavencoffe A., Mariot P., Gackiere F., Bidaux G., Urbain R., Gosset P., Delcourt P., Fleurisse L., Slomianny C., Dewailly E., Mauroy B., Bonnal J.L., Skryma R. and Prevarskaya N. (2009). Intermediate-conductance Ca2+-activated K+ channels (IKCa1) regulate human prostate cancer cell proliferation through a close control of calcium entry. Oncogene 28, 1792-1806.
25. Lauffenburger D.A. and Horwitz A.F. (1996). Cell migration: a physically integrated molecular process. Cell 84, 359-369.
26. Lougheed J.C., Holton J.M., Alber T., Bazan J.F. and Handel T.M. (2001). Structure of melanoma inhibitory activity protein, a member of a recently identified family of secreted proteins. Proc. Natl. Acad. Sci. USA 98, 5515-5520.
27. Marr D.G., Poser I., Shellman Y.G., Bosserhoff A.K. and Norris D.A. (2004). Ultraviolet radiation induces release of MIA: a new mechanism for UVR-induced progression of melanoma. Int. J. Oncol. 25, 105-111.
28. Moser M., Bosserhoff A.K., Hunziker E.B., Sandell L., Fassler R. and Buettner R. (2002). Ultrastructural cartilage abnormalities in MIA/CD-RAP-deficient mice. Mol. Cell. Biol. 22, 1438-1445.
29. Parent C.A. and Devreotes P.N. (1999). A cell's sense of direction. Science 284, 765-770.
30. Pettit E.J. and Fay F.S. (1998). Cytosolic free calcium and the cytoskeleton in the control of leukocyte chemotaxis. Physiol. Rev. 78, 949-967.
31. Riechers A., Schmidt J., Konig B. and Bosserhoff A.K. (2009). Heterogeneous transition metal-based fluorescence polarization (HTFP) assay for probing protein interactions. Biotechniques 47, 837-844.
32. Scheier B., Amaria R., Lewis K. and Gonzalez R. (2011). Novel therapies in melanoma. Immunotherapy 3, 1461-1469.
33. Schmid R., Schiffner S., Opolka A., Grassel S., Schubert T., Moser M. and Bosserhoff A.K. (2010). Enhanced cartilage regeneration in MIA/CD-RAP deficient mice. Cell Death Dis. 1, e97.
34. Schmidt J. and Bosserhoff A.K. (2009). Processing of MIA protein during melanoma cell migration. Int. J. Cancer 125, 1587-1594.
35. Schmidt J., Friebel K., Schönherr R., Coppolino M.G. and Bosserhoff A.K. (2010). Migration-associated secretion of melanoma inhibitory activity (MIA) at the cell rear is supported by KCa3.1 potassium channels. Cell Res. 20, 1224-1238.
36. Schmidt J., Riechers A., Stoll R., Amann T., Fink F., Spruss T., Gronwald W., Konig B., Hellerbrand C. and Bosserhoff A.K. (2012). Targeting melanoma metastasis and immunosuppression with a new mode of melanoma inhibitory activity (MIA) protein inhibition. PLoS One 7, e37941.
37. + channel. A prerequisite for migration of transformed Madin-Darby canine kidney focus cells. J. Clin. Invest. 93, 1631-1636.
38. Schwab A., Gabriel K., Finsterwalder F., Folprecht G., Greger R., Kramer A. and Oberleithner H. (1995). Polarized ion transport during migration of transformed Madin-Darby canine kidney cells. Pflugers Arch. 430, 802-807.
39. Schwab A., Nechyporuk-Zloy V., Fabian A. and Stock C. (2007). Cells move when ions and water flow. Pflugers Arch. 453, 421-432.
40. Segal N.H., Pavlidis P., Noble W.S., Antonescu C.R., Viale A., Wesley U.V., Busam K., Gallardo H., DeSantis D., Brennan M.F., Cordon-Cardo C., Wolchok J.D. and Houghton A.N. (2003). Classification of clear-cell sarcoma as a subtype of melanoma by genomic profiling. J. Clin. Oncol. 21, 1775-1781.
41. Stahlecker J., Gauger A., Bosserhoff A., Buttner R., Ring J. and Hein R. (2000). MIA as a reliable tumor marker in the serum of patients with malignant melanoma. Anticancer Res. 20, 5041-5044.
42. Stoll R. and Bosserhoff A. (2008). Extracellular SH3 domain containing proteins - features of a new protein family. Curr. Protein Pept. Sci. 9, 221-226.
43. Stoll R., Renner C., Ambrosius D., Golob M., Voelter W., Buettner R., Bosserhoff A.K. and Holak T. A. (2000). Sequence-specific 1H, 13C, and 15N assignment of the human melanoma inhibitory activity (MIA) protein. J. Biomol. NMR 17, 87-88.
44. Stoll R., Renner C., Zweckstetter M., Bruggert M., Ambrosius D., Palme S., Engh R.A., Golob M., Breibach I., Buettner R., Voelter W., Holak T.A. and Bosserhoff A.K. (2001). The extracellular human melanoma inhibitory activity (MIA) protein adopts an SH3 domain-like fold. EMBO J. 20, 340-349.
45. Stoll R., Renner C., Buettner R., Voelter W., Bosserhoff A.K. and Holak T.A. (2003). Backbone dynamics of the human MIA protein studied by (15)N NMR relaxation: implications for extended interactions of SH3 domains. Protein Sci. 12, 510-519.
46. + channels in human melanoma cells are up-regulated by hypoxia involving hypoxia-inducible factor-1alpha and the von Hippel-Lindau protein. J. Physiol. 571, 349-359.
47. Varney M.L., Johansson S.L. and Singh R.K. (2006). Distinct expression of CXCL8 and its receptors CXCR1 and CXCR2 and their association with vessel density and aggressiveness in malignant melanoma. Am. J. Clin. Pathol. 125, 209-216.
48. + channel mediates B lymphoma cell cycle progression induced by serum. Pflugers Arch. 454, 945-956.